Poziotinib Binding Strategy for Resistant HER2 Exon 21 Mutations
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current targeted therapies for HER2 mutations, particularly exon 20 insertions, show limited efficacy and resistance across various cancer types, highlighting the need for a detailed understanding and effective treatment strategies for these mutations.
Innovation Solution
Administration of poziotinib, a tyrosine kinase inhibitor, specifically targeting HER2 exon 21 mutations, which overcomes steric hindrance and inhibits these mutants at low nanomolar concentrations, even in cases resistant to other TKIs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing tyrosine kinase inhibitors (neratinib, afatinib, dacomitinib) are used to treat HER2 exon 21 mutations, then some anti-tumor activity is achieved, but resistance develops and efficacy is limited particularly for exon 20 insertion mutations
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of quinazoline-based TKIs to create poziotinib, which has altered binding characteristics that overcome resistance mechanisms. The structural modifications enable poziotinib to maintain efficacy against HER2 exon 21 mutations including L755P and exon 20 insertions where previous TKIs failed, effectively changing the drug's interaction parameters with the mutant receptor.
2Duration of action of stationary object
If covalent second-generation TKIs are administered to achieve irreversible inhibition, then prolonged duration of action is achieved, but steric hindrance reduces binding efficacy to mutant HER2
Solution Approach 1:
The patent applies local quality by introducing specific structural modifications at particular regions of the quinazoline molecule. These localized changes optimize the drug's ability to access and bind to the mutant HER2 binding site while maintaining the covalent irreversible inhibition mechanism, thereby resolving the conflict between prolonged duration and binding ease.
3Measurement precision
If broad molecular profiling is performed to detect HER2 mutations, then accurate diagnosis is achieved, but no approved targeted therapies exist specifically for HER2 mutations
Solution Approach 1:
The patent applies universality by developing poziotinib as a pan-HER inhibitor that maintains efficacy across multiple HER2 mutation types (exon 19, exon 20, exon 21 mutations). This multi-functional capability addresses the unmet need for a single targeted therapy that can treat various HER2 mutant cancers identified through molecular profiling, eliminating the need for mutation-specific treatments.
Data Source
AI summary
The present disclosure provides methods of treating cancer in a patient determined to have an HER2 exon 21 mutation by administering a third-generation tyrosine kinase inhibitor, such as poziotinib.